Decheng Capital Overview
- Investor Type
- Venture Capital
- Status
- Active
- Professionals
- 12
- Investments
- 95
- Portfolio
- 40
- Exits
- 29
Decheng Capital General Information
Description
Founded in 2012, Decheng Capital is a venture capital firm based in Menlo Park, California. The firm has a regional office based in Shanghai, China, and New York, New York. The firm seeks to invest in early-stage life science companies with revolutionary technologies and growth-stage healthcare companies.
Contact Information
Website
www.decheng.com
Year Founded
2012
Investor Status
Actively Seeking New Investments
Primary Investor Type
Venture Capital
Other Investor Types
Growth/Expansion
Primary Office
- 3000 Sand Hill Road
- Building 2, Suite 110
- Menlo Park, CA 94025
- United States
+1 (650) 000-0000
Decheng Capital Investments (95)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
|---|---|---|---|---|---|---|
| Nalu | 17-Feb-2022 | Later Stage VC | 00000 | Therapeutic Devices | Generating Revenue | |
| 00000000 000000 00 | 01-Feb-2022 | 00 000000000 | 000.00 | Surgical Devices | Generating Revenue | |
| 0000000 000 | 20-Jan-2022 | 00000 00000 | 00000 | Drug Discovery | Generating Revenue | 00000000 000 00.0 |
| 0000 0000000000000 | 27-Dec-2021 | 00000 00000 | 0000 | Drug Discovery | Clinical Trials - Phase 2 | |
| 00000000 | 16-Nov-2021 | 00000 00000 | 00000 | Drug Discovery | Clinical Trials - Phase 2 | |
| 000000 000000 0000 | 14-Sep-2021 | 0000 | 0000 | Pharmaceuticals | Generating Revenue/Not Profitable | 00000000 000 00.0 |
| 0000 0000000000000 | 10-Sep-2021 | 00000 00000 | 0000 | Drug Discovery | Clinical Trials - Phase 2 | |
| 0000000 0000000000 | 09-Sep-2021 | 00000 00000 | 00000 | Biotechnology | Generating Revenue | 000000 0000 00. |
| Haoxinqing | 06-Sep-2021 | Later Stage VC | 000.00 | Clinics/Outpatient Services | Generating Revenue | |
| GRIT Biotechnology | 15-Jul-2021 | Early Stage VC | Drug Discovery | Pre-Clinical Trials |
Decheng Capital Exits (29)
| Company Name | Exit Date | Exit Type | Exit Size |
|---|---|---|---|
| Cue Health | 24-Sep-2021 | IPO | 00000 |
| 0000000 | 20-Sep-2021 | 000000000000000000 | 00000 |
| 00000000 | 01-Sep-2021 | 000000000 00000000 | |
| 0000 0000000000 | 27-Aug-2021 | 0000000 000000 | |
| 00000 | 18-Aug-2021 | 000000000000000000 | 00.00 |
| 00000 | 22-Jul-2021 | 0000000 000000 | 00000 |
| 00000 000000000000 | 05-Feb-2021 | 000 | 00000 |
| 00000000 | 18-Dec-2020 | 000000000000000000 | 00.00 |
| ReadCoor | 13-Oct-2020 | Merger/Acquisition | 00000 |
| Everest Medicines | 09-Oct-2020 | IPO | 00000 |
Decheng Capital Fund Performance
| Fund Name | Vintage | Size | Dry Powder | DPI | RVPI | TVPI | IRR |
|---|
This information is available in the PitchBook Platform. To explore Decheng Capital‘s full profile, request access.
Request a free trialDecheng Capital Investments by Industry, Year, and Region
Investments by Industry
Investments by Year
Investments by Region
PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.
Request a free trialDecheng Capital Team (15)
| Name | Title | Deals | Funds | Boards | Office |
|---|---|---|---|---|---|
| Xiangmin Cui Ph.D | Founder & Managing Director | 00 | 0 | 0 | Menlo Park, CA |
| Daniel Zabrowski Ph.D | Venture Partner | 0 | 0 | 0 | Menlo Park, CA |
| Nick Pliam Ph.D | Partner | 0 | 0 | 0 | Menlo Park, CA |
| Qiang Xu Ph.D | Partner | 0 | 0 | 0 | Shanghai, China |
| Victor Tong Jr. | Partner | 0 | 0 | 0 | Shanghai, China |
Decheng Capital Co-Investors (203)
| Name | With | Exits | Lead Partner | Series | Industry |
|---|---|---|---|---|---|
| OrbiMed | 6 | 0 | 0 |
|
|
| Foresite Capital Management | 0 | 0 | 0 |
|
|
| Hillhouse Capital Group | 0 | 0 | 0 |
|
|
| Sherpa Healthcare Partners | 0 | 0 |
|
|
|
| ARCH Venture Partners | 0 | 0 | 0 |
|
|